抗IL-17成功治疗红皮病型银屑病:一个病例系列。

IF 0.6 4区医学 Q4 DERMATOLOGY

Acta Dermatovenerologica Croatica Pub Date : 2021-11-01

Nicoletta Bernardini, Nevena Skroza, Ilaria Proietti, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Veronica Balduzzi, Concetta Potenza

{"title":"抗IL-17成功治疗红皮病型银屑病:一个病例系列。","authors":"Nicoletta Bernardini, Nevena Skroza, Ilaria Proietti, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Veronica Balduzzi, Concetta Potenza","doi":"","DOIUrl":null,"url":null,"abstract":"Erythrodermic psoriasis (EP) is a very rare but extremely severe subtype of chronic plaque psoriasis. Its pathogenesis still remains unknown, and current therapeutic strategies frequently end in failure. Erythrodermic psoriasis often requires hospitalization in order to control any kind of possible serious complications. Treatment of EP is a challenge for clinicians because international guidelines are lacking. Nevertheless, Th17 has been shown to be the second-most predominant T-cell type after Th2 in EP lesions. There is a growing body of evidence supporting the safety and efficacy of biologics in rapidly achieving near-total clearance of EP, particularly within the IL-17 class. Herein we report a series of 5 cases of EP successfully treated with anti-interleukines 17: Ixekizumab and Secukinumab.","PeriodicalId":50903,"journal":{"name":"Acta Dermatovenerologica Croatica","volume":"29 4","pages":"191-195"},"PeriodicalIF":0.6000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series.\",\"authors\":\"Nicoletta Bernardini, Nevena Skroza, Ilaria Proietti, Alessandra Mambrin, Anna Marchesiello, Ersilia Tolino, Veronica Balduzzi, Concetta Potenza\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Erythrodermic psoriasis (EP) is a very rare but extremely severe subtype of chronic plaque psoriasis. Its pathogenesis still remains unknown, and current therapeutic strategies frequently end in failure. Erythrodermic psoriasis often requires hospitalization in order to control any kind of possible serious complications. Treatment of EP is a challenge for clinicians because international guidelines are lacking. Nevertheless, Th17 has been shown to be the second-most predominant T-cell type after Th2 in EP lesions. There is a growing body of evidence supporting the safety and efficacy of biologics in rapidly achieving near-total clearance of EP, particularly within the IL-17 class. Herein we report a series of 5 cases of EP successfully treated with anti-interleukines 17: Ixekizumab and Secukinumab.\",\"PeriodicalId\":50903,\"journal\":{\"name\":\"Acta Dermatovenerologica Croatica\",\"volume\":\"29 4\",\"pages\":\"191-195\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Dermatovenerologica Croatica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Dermatovenerologica Croatica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

红皮病型牛皮癣(EP)是一种非常罕见但非常严重的慢性斑块型牛皮癣亚型。其发病机制尚不清楚，目前的治疗策略往往以失败告终。红皮病型牛皮癣通常需要住院治疗，以控制任何可能的严重并发症。由于缺乏国际指导方针，EP的治疗对临床医生来说是一个挑战。然而，在EP病变中，Th17已被证明是仅次于Th2的第二大主要t细胞类型。越来越多的证据支持生物制剂在快速接近完全清除EP方面的安全性和有效性，特别是在IL-17类中。在此，我们报告了5例成功治疗EP的抗白介素17:Ixekizumab和Secukinumab。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series.

Erythrodermic psoriasis (EP) is a very rare but extremely severe subtype of chronic plaque psoriasis. Its pathogenesis still remains unknown, and current therapeutic strategies frequently end in failure. Erythrodermic psoriasis often requires hospitalization in order to control any kind of possible serious complications. Treatment of EP is a challenge for clinicians because international guidelines are lacking. Nevertheless, Th17 has been shown to be the second-most predominant T-cell type after Th2 in EP lesions. There is a growing body of evidence supporting the safety and efficacy of biologics in rapidly achieving near-total clearance of EP, particularly within the IL-17 class. Herein we report a series of 5 cases of EP successfully treated with anti-interleukines 17: Ixekizumab and Secukinumab.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta Dermatovenerologica Croatica 医学-皮肤病学

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Acta Dermatovenerologica Croatica (ADC) aims to provide dermatovenerologists with up-to-date information on all aspects of the diagnosis and management of skin and venereal diseases. Accepted articles regularly include original scientific articles, short scientific communications, clinical articles, case reports, reviews, reports, news and correspondence. ADC is guided by a distinguished, international editorial board and encourages approach to continuing medical education for dermatovenerologists.